- Home
- OMH vs CERO Comparison
OMH vs CERO Comparison
Compare OMH & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMH
- CERO
- Stock Information
- Founded
- OMH 2015
- CERO 2017
- Country
- OMH Singapore
- CERO United States
- Employees
- OMH N/A
- CERO N/A
- Industry
- OMH Real Estate
- CERO
- Sector
- OMH Finance
- CERO
- Exchange
- OMH Nasdaq
- CERO Nasdaq
- Market Cap
- OMH 13.6M
- CERO 3.5M
- IPO Year
- OMH 2023
- CERO N/A
- Fundamental
- Price
- OMH $1.47
- CERO $8.90
- Analyst Decision
- OMH Hold
- CERO Strong Buy
- Analyst Count
- OMH 1
- CERO 2
- Target Price
- OMH N/A
- CERO $45.00
- AVG Volume (30 Days)
- OMH 179.3K
- CERO 3.3M
- Earning Date
- OMH 07-18-2025
- CERO 08-13-2025
- Dividend Yield
- OMH N/A
- CERO N/A
- EPS Growth
- OMH N/A
- CERO N/A
- EPS
- OMH N/A
- CERO N/A
- Revenue
- OMH $7,976,578.00
- CERO N/A
- Revenue This Year
- OMH $28.40
- CERO N/A
- Revenue Next Year
- OMH $23.07
- CERO N/A
- P/E Ratio
- OMH N/A
- CERO N/A
- Revenue Growth
- OMH 117.53
- CERO N/A
- 52 Week Low
- OMH $0.59
- CERO $6.71
- 52 Week High
- OMH $6.20
- CERO $895.40
- Technical
- Relative Strength Index (RSI)
- OMH 45.64
- CERO 46.23
- Support Level
- OMH $1.32
- CERO $8.50
- Resistance Level
- OMH $1.60
- CERO $9.73
- Average True Range (ATR)
- OMH 0.10
- CERO 1.20
- MACD
- OMH 0.03
- CERO -0.01
- Stochastic Oscillator
- OMH 53.07
- CERO 14.54
About OMH Ohmyhome Limited
Ohmyhome Ltd is a data and technology-driven property technology company based in Singapore. Through its subsidiaries, it operates a one-stop-shop property platform that provides end-to-end property solutions and services for its customers, which comprises brokerage services and emerging and other services, such as home renovation and furnishing services, listing and research, mortgage referral, legal services, and insurance referral services. The company derives its revenues from two sources: revenue from brokerage services, property management services, and revenue from emerging and other services.
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.